Page 77 - 《中国药房》2021年16期

400 15 000
5 000
300 10 000
intensity 200 intensity intensity 2 500

100 5 000
0 0 0
0 2.5 5.0 7.5 0 2.5 5.0 7.5 10.0 0 2.5 5.0 7.5 10.0
t，min t，min t，min
1 500 50 000
40 000

1 000 30 000
intensity intensity 20 000 intensity 25 000
500
10 000

0 0 0
0 2.5 5.0 7.5 0 2.5 5.0 7.5 10.0 0 2.5 5.0 7.5 10.0
t，min t，min t，min

5 000 7 500
1 000
intensity 500 intensity 2 500 intensity 5 000
2 500

0 0 0
0 2.5 5.0 7.5 0 2.5 5.0 7.5 10.0 0 2.5 5.0 7.5 10.0
t，min t，min t，min
200
15 000
150 500
intensity 100 intensity 10 000 intensity 250

50 5 000
0 0 0
0 2.5 5.0 7.5 0 2.5 5.0 7.5 10.0 0 2.5 5.0 7.5 10.0
t，min t，min t，min
150 4 000
15 000
3 000
100 10 000
intensity intensity intensity 2 000
50 5 000
1 000
0 0 0
0 2.5 5.0 7.5 0 2.5 5.0 7.5 10.0 0 2.5 5.0 7.5 10.0
t，min t，min t，min
100 10 000 4 000
75 7 500 3 000
intensity 50 intensity 5 000 intensity 2 000

25 2 500 1 000
0 0 0
0 2.5 5.0 7.5 0 2.5 5.0 7.5 10.0 0 2.5 5.0 7.5 10.0
t，min t，min t，min
A. 空白溶液 B.混合对照品溶液 C.供试品溶液
注：1.苯甲酰乌头原碱；2.苯甲酰新乌头原碱；3.苯甲酰次乌头原碱；4.乌头碱；5.新乌头碱；6.次乌头碱；7.胡椒碱；8.没食子酸
Note：1. benzoylaconitine；2. benzoylneoaconitine；3. benzoylhypoaconitine；4. aconitine；5. neoaconitine；6. hypoaconitine；7. piperine；8. gal-
lic acid
图 2 苯甲酰乌头原碱等8 种成分的多反应监测模式图谱
Fig 2 Multiple reaction monitoring chromatograms of 8 components as benzoylaconitine

中国药房 2021年第32卷第16期 China Pharmacy 2021 Vol. 32 No. 16 ·1991 ·